Advertisement
Screener

Karyopharm Therapeutics Inc. (KPTI) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Karyopharm Therapeutics Inc. Stock-Based Compensation

Karyopharm Therapeutics Inc. (KPTI) reported Stock-Based Compensation of $4.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-13

  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.93M, a 49.02% decline year-over-year.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.01M, a 15.53% decline year-over-year.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.90M, a 1.01% increase year-over-year.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.80M, a 32.97% decline year-over-year.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $14.05M, a 23.75% decline from fiscal 2024.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $18.43M, a 15.12% decline from fiscal 2023.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $21.71M, a 38.67% decline from fiscal 2022.
  • Karyopharm Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $35.40M, a 18.86% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 57 monthShare-based Payment Arrangement, Noncash Expense 60 monthShare-based Payment Arrangement, Noncash Expense 63 month
2026-06-30$1.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$4.94M
10-Q · filed 2026-08-13
$8.84M
derived: sum of 3 quarters · filed 2026-08-13
$11.64M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$3.01M
10-Q · filed 2026-05-14
$6.91M
derived: sum of 2 quarters · filed 2026-05-14
$9.71M
derived: sum of 3 quarters · filed 2026-05-14
$13.50M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$6.71M
derived: sum of 2 quarters · filed 2026-02-13
$10.49M
derived: sum of 3 quarters · filed 2026-08-13
$14.05M
10-K · filed 2026-02-13
2025-09-30$2.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$6.59M
derived: sum of 2 quarters · filed 2026-08-13
$10.15M
10-Q · filed 2025-11-03
$14.01M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$3.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$7.34M
10-Q · filed 2026-08-13
$11.21M
derived: sum of 3 quarters · filed 2026-08-13
$15.39M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$3.56M
10-Q · filed 2026-05-14
$7.42M
derived: sum of 2 quarters · filed 2026-05-14
$11.61M
derived: sum of 3 quarters · filed 2026-05-14
$17.02M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$3.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$8.05M
derived: sum of 2 quarters · filed 2026-02-13
$13.46M
derived: sum of 3 quarters · filed 2026-02-13
$18.43M
10-K · filed 2026-02-13
2024-09-30$4.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$9.59M
derived: sum of 2 quarters · filed 2025-11-03
$14.56M
10-Q · filed 2025-11-03
$19.74M
derived: sum of 4 quarters · filed 2026-02-13
2024-06-30$5.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
$10.38M
10-Q · filed 2025-08-11
$15.56M
derived: sum of 3 quarters · filed 2026-02-13
$20.64M
derived: sum of 4 quarters · filed 2026-02-13
2024-03-31$4.97M
10-Q · filed 2025-05-12
$10.15M
derived: sum of 2 quarters · filed 2026-02-13
$15.23M
derived: sum of 3 quarters · filed 2026-02-13
$21.29M
derived: sum of 4 quarters · filed 2026-02-13
2023-12-31$5.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$10.26M
derived: sum of 2 quarters · filed 2026-02-13
$16.32M
derived: sum of 3 quarters · filed 2026-02-13
$21.71M
10-K · filed 2026-02-13
2023-09-30$5.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
$11.14M
derived: sum of 2 quarters · filed 2024-11-05
$16.53M
10-Q · filed 2024-11-05
$22.70M
derived: sum of 4 quarters · filed 2025-02-19
2023-06-30$6.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$11.45M
10-Q · filed 2024-08-06
$17.62M
derived: sum of 3 quarters · filed 2025-02-19
$24.42M
derived: sum of 4 quarters · filed 2025-02-19
2023-03-31$5.39M
10-Q · filed 2024-05-08
$11.56M
derived: sum of 2 quarters · filed 2025-02-19
$18.36M
derived: sum of 3 quarters · filed 2025-02-19
$33.45M
derived: sum of 4 quarters · filed 2025-02-19
2022-12-31$6.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19
$12.97M
derived: sum of 2 quarters · filed 2025-02-19
$28.06M
derived: sum of 3 quarters · filed 2025-02-19
$35.40M
10-K · filed 2025-02-19
2022-09-30$6.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$21.89M
derived: sum of 2 quarters · filed 2023-11-02
$29.23M
10-Q · filed 2023-11-02
$36.09M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$15.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
$22.43M
10-Q · filed 2023-08-02
$29.30M
derived: sum of 3 quarters · filed 2024-02-29
$36.72M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$7.34M
10-Q · filed 2023-05-04
$14.21M
derived: sum of 2 quarters · filed 2024-02-29
$21.63M
derived: sum of 3 quarters · filed 2024-02-29
$29.76M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$6.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$14.29M
derived: sum of 2 quarters · filed 2024-02-29
$22.42M
derived: sum of 3 quarters · filed 2024-02-29
$29.78M
10-K · filed 2024-02-29
2021-09-30$7.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$15.55M
derived: sum of 2 quarters · filed 2022-11-03
$22.91M
10-Q · filed 2022-11-03
$29.23M
derived: sum of 4 quarters · filed 2023-02-17
2021-06-30$8.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$15.49M
10-Q · filed 2022-08-04
$21.81M
derived: sum of 3 quarters · filed 2023-02-17
$28.32M
derived: sum of 4 quarters · filed 2023-02-17
2021-03-31$7.36M
10-Q · filed 2022-05-05
$13.67M
derived: sum of 2 quarters · filed 2023-02-17
$20.19M
derived: sum of 3 quarters · filed 2023-02-17
$26.61M
derived: sum of 4 quarters · filed 2023-02-17
2020-12-31$6.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17
$12.83M
derived: sum of 2 quarters · filed 2023-02-17
$19.25M
derived: sum of 3 quarters · filed 2023-02-17
$24.41M
10-K · filed 2023-02-17
2020-09-30$6.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$12.94M
derived: sum of 2 quarters · filed 2021-11-03
$18.09M
10-Q · filed 2021-11-03
$21.64M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$6.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$11.58M
10-Q · filed 2021-08-05
$15.13M
derived: sum of 3 quarters · filed 2022-03-01
$18.85M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$5.15M
10-Q · filed 2021-05-04
$8.70M
derived: sum of 2 quarters · filed 2022-03-01
$12.42M
derived: sum of 3 quarters · filed 2022-03-01
$16.54M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$3.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$7.27M
derived: sum of 2 quarters · filed 2022-03-01
$11.38M
derived: sum of 3 quarters · filed 2022-03-01
$15.29M
10-K · filed 2022-03-01
2019-09-30$3.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$7.83M
derived: sum of 2 quarters · filed 2020-11-02
$11.74M
10-Q · filed 2020-11-02
$15.64M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$4.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
$8.02M
10-Q · filed 2020-08-04
$11.92M
derived: sum of 3 quarters · filed 2021-02-24
$16.69M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$3.91M
10-Q · filed 2020-05-05
$7.80M
derived: sum of 2 quarters · filed 2021-02-24
$12.58M
derived: sum of 3 quarters · filed 2021-02-24
$17.02M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$8.67M
derived: sum of 2 quarters · filed 2021-02-24
$13.11M
derived: sum of 3 quarters · filed 2021-02-24
$17.27M
10-K · filed 2021-02-24
2018-09-30$4.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04
$9.21M
derived: sum of 2 quarters · filed 2019-11-04
$13.38M
10-Q · filed 2019-11-04
$17.88M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$4.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$8.60M
10-Q · filed 2019-08-07
$13.10M
derived: sum of 3 quarters · filed 2020-02-26
$17.97M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$4.16M
10-Q · filed 2019-05-09
$8.66M
derived: sum of 2 quarters · filed 2020-02-26
$13.53M
derived: sum of 3 quarters · filed 2020-02-26
$18.66M
derived: sum of 4 quarters · filed 2020-02-26
2017-12-31$4.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$9.37M
derived: sum of 2 quarters · filed 2020-02-26
$14.50M
derived: sum of 3 quarters · filed 2020-02-26
$20.41M
10-K · filed 2020-02-26
2017-09-30$4.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$10.00M
derived: sum of 2 quarters · filed 2018-11-08
$15.91M
10-Q · filed 2018-11-08
$21.03M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$5.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$11.04M
10-Q · filed 2018-08-07
$16.16M
derived: sum of 3 quarters · filed 2019-02-28
$21.76M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$5.91M
10-Q · filed 2018-05-10
$11.04M
derived: sum of 2 quarters · filed 2019-02-28
$16.63M
derived: sum of 3 quarters · filed 2019-02-28
$23.03M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31$5.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
$10.72M
derived: sum of 2 quarters · filed 2019-02-28
$17.13M
derived: sum of 3 quarters · filed 2019-02-28
$22.28M
10-K · filed 2019-02-28
2016-09-30$5.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$12.00M
derived: sum of 2 quarters · filed 2017-11-02
$17.16M
10-Q · filed 2017-11-02
$22.50M
derived: sum of 4 quarters · filed 2018-03-15
2016-06-30$6.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
$11.56M
10-Q · filed 2017-08-08
$16.91M
derived: sum of 3 quarters · filed 2018-03-15
$20.39M
derived: sum of 4 quarters · filed 2018-03-15
2016-03-31$5.16M
10-Q · filed 2017-05-04
$10.50M
derived: sum of 2 quarters · filed 2018-03-15
$13.98M
derived: sum of 3 quarters · filed 2018-03-15
$18.47M
derived: sum of 4 quarters · filed 2018-03-15
2015-12-31$5.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$8.83M
derived: sum of 2 quarters · filed 2018-03-15
$13.31M
derived: sum of 3 quarters · filed 2018-03-15
$17.06M
10-K · filed 2018-03-15
2015-09-30$3.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$7.96M
derived: sum of 2 quarters · filed 2016-11-07
$11.71M
10-Q · filed 2016-11-07
$16.30M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$4.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$8.23M
10-Q · filed 2016-08-04
$12.82M
derived: sum of 3 quarters · filed 2017-03-16
$15.74M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$3.75M
10-Q · filed 2016-05-09
$8.34M
derived: sum of 2 quarters · filed 2017-03-16
$11.26M
derived: sum of 3 quarters · filed 2017-03-16
$15.14M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$4.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$7.51M
derived: sum of 2 quarters · filed 2017-03-16
$11.39M
derived: sum of 3 quarters · filed 2017-03-16
$14.24M
10-K · filed 2017-03-16
2014-09-30$2.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$6.80M
derived: sum of 2 quarters · filed 2015-11-09
$9.65M
10-Q · filed 2015-11-09
$11.66M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$3.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
$6.73M
10-Q · filed 2015-08-10
$8.75M
derived: sum of 3 quarters · filed 2016-03-15
$10.07M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$2.85M
10-Q · filed 2015-05-11
$4.86M
derived: sum of 2 quarters · filed 2016-03-15
$6.18M
derived: sum of 3 quarters · filed 2016-03-15
$6.43M
derived: sum of 4 quarters · filed 2016-03-15
$7.35M
10-Q · filed 2014-05-08
2013-12-31$2.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$3.34M
derived: sum of 2 quarters · filed 2016-03-15
$3.58M
derived: sum of 3 quarters · filed 2016-03-15
$3.79M
10-K · filed 2016-03-15
$4.51M
10-K · filed 2014-03-21
2013-09-30$1.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
$1.56M
derived: sum of 2 quarters · filed 2014-11-10
$1.77M
10-Q · filed 2014-11-10
$2.09M
derived: sum of 4 quarters · filed 2015-03-13
$2.49M
10-Q/A · filed 2013-12-23
2013-06-30$242.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$446.00K
10-Q · filed 2014-08-07
$770.00K
derived: sum of 3 quarters · filed 2015-03-13
2013-03-31$204.00K
10-Q · filed 2014-05-08
$528.00K
derived: sum of 2 quarters · filed 2015-03-13
2012-12-31$324.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-13
$653.00K
10-K · filed 2015-03-13
2012-09-30$329.00K
10-Q/A · filed 2013-12-23
2011-12-31$24.00K
10-K · filed 2014-03-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
CervoMed Inc. (CRVO)United States$0.038B-1.39
Celularity Inc (CELU)United States$0.038B-0.34
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Kairos Pharma, LTD. (KAPA)United States$0.041B
PMGC Holdings Inc. (ELAB)United States$0.037B
BriaCell Therapeutics Corp. (BCTX)$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45